New Report Available: Lithuania Pharmaceuticals & Healthcare Report Q2 2013
We expect the Lithuanian pharmaceutical market to continue to develop steadily over the coming years, on account of demographic and epidemiological factors. However, its small population and downward pressures on prices will continue to hamper the overall potential earnings in the country for pharmaceutical companies. Nevertheless, niche areas, such as biopharmaceuticals, will remain of interest to foreign majors, also from the point of view of exports.
View full press release